Biotech · Private company
IO Biotech
Track this companyFree. Adds IO Biotech to your Dealase workspace and tells you when its record changes.
Clinical trials65 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- IO102-IO103Phase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IO102-IO103Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IO102-IO103 in combination with pembrolizumabPhase 2 · Lung Cancer Non Small CellClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab KEYTRUDA®Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsPHASE2 · RECRUITING · started Dec 21, 2023ClinicalTrials.gov NCT05280314 · fetched Nov 12, 2026
- Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 14, 2023ClinicalTrials.gov NCT05977907 · fetched Nov 12, 2026
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 9, 2023ClinicalTrials.gov NCT05912244 · fetched Nov 12, 2026
- IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 19, 2023ClinicalTrials.gov NCT05843448 · fetched Nov 12, 2026
- IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)PHASE3 · ACTIVE_NOT_RECRUITING · started May 17, 2022ClinicalTrials.gov NCT05155254 · fetched Nov 12, 2026
- IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCPHASE2 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05077709 · fetched Nov 12, 2026